Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Regarding diabetic complications: 11.2% Diabetic retinopathy (using a portable fundus camera), 14.41% diabetic kidney disease (using CKD-EP), 26.34% diabetic peripheral neuropathy (neuropathic symptom score and Semmes-Weintein monofilament), 9.66% cardiovascular autonomic neuropathy (spectral analysis and Ewing tests) and 11.75% cognitive decline (using Minimental)
Semax Semax is a synthetic peptide developed in Russia, initially for the treatment of optic nerve diseases
But for now, the strongest evidence is still preclinical
Research involving BPC-157 is still developing, and it is not approved by the United States Food and Drug Administration for treating medical conditions
That decision is jurisdiction-specific, and the regulatory picture in the UAE is its own thing
